A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. We have successfully developed our first product, mavorixafor, in its first indication. Mavorixafor is an orally available, small-molecule selective antagonist of chemokine receptor CXCR4. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, we believe that mavorixafor has the potential to benefit people with a range of immunodeficiencies – a therapeutic market that is principally served by injectable therapies frequently associated with treatment-limiting adverse events. In April 2024, the U.S. Food and Drug Administration (“FDA”) approved mavorixafor, which is being marketed in the U.S.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 34M | - | 0 | 0 | 0 | - |
| Net Income | -95M | -37M | -101M | -96M | -103M | -62M |
| EPS | $-8.87 | $-5.70 | $-17.10 | $-45.60 | $-119.70 | $-92.70 |
| Free Cash Flow | 0 | -131M | -97M | -77M | -72M | -60M |
| ROIC | -114.8% | -38.4% | -95.7% | -90.7% | -406.0% | -58.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 1.23 | 3.41 | 1.07 | 0.45 | 0.53 | 0.46 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -99M | -36M | -108M | -88M | -85M | -60M |
| Operating Margin | -291.1% | - | - | - | - | - |
| ROE | -154.3% | -102.3% | -198.0% | -139.3% | -159.3% | -85.3% |
| Shares Outstanding | 87M | 7M | 6M | 2M | 4M | 1M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | 0 | N/A | 0 | 0 | 0 | N/A | 34M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -46M | -52M | -60M | -85M | -88M | -108M | -36M | -99M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -291.1% |
| Net Income | -43M | -53M | -62M | -103M | -96M | -101M | -37M | -95M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -279.9% |
| Non-Recurring | 0 | 0 | 0 | 9.8M | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -100.7% | -35.8% | -58.6% | N/M | -90.7% | -95.7% | -38.4% | -114.8% |
| ROE | -107.1% | -41.3% | -85.3% | -159.3% | -139.3% | -198.0% | -102.3% | -154.3% |
| ROA | -73.4% | -33.2% | -50.6% | -87.6% | -70.7% | -68.7% | -25.5% | -58.1% |
| Cash Flow | ||||||||
| Op. Cash Flow | -41M | -48M | -59M | -71M | -77M | -97M | -131M | -103M |
| Free Cash Flow | -41M | -48M | -60M | -72M | -77M | -97M | -131M | 0 |
| Owner Earnings | -47M | -50M | -65M | -78M | -83M | -106M | -140M | -112M |
| CapEx | 34K | 174K | 1.4M | 615K | 103K | 60K | 326K | 0 |
| Maint. CapEx | 155K | 103K | 351K | 499K | 513K | 419K | 796K | 796K |
| Growth CapEx | 0 | 71K | 1.0M | 116K | 0 | 0 | 0 | 0 |
| D&A | 155K | 103K | 351K | 499K | 513K | 419K | 796K | 796K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 2.0M | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.8% | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 5.6M | 2.1M | 5.4M | 6.2M | 5.2M | 8.7M | 8.2M | 8.2M |
| Debt Repayment | 4.7M | 9.4M | 0 | 0 | 795K | 2.1M | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -23M | -106M | -46M | -48M | -88M | -45M | 20M | 6.4M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 70M |
| Long-Term Debt | 7.9M | 20M | 33M | 33M | 32M | 55M | 75M | 75M |
| Debt/Equity | 0.37 | 0.16 | 0.46 | 0.53 | 0.45 | 1.07 | 3.41 | 1.23 |
| Interest Coverage | -44.2 | -24.1 | -22.3 | -23.4 | -21.9 | -18.6 | -4.2 | -4.2 |
| Equity | 22M | 129M | 73M | 64M | 74M | 51M | 22M | 62M |
| Total Assets | 36M | 161M | 123M | 117M | 156M | 147M | 146M | 164M |
| Total Liabilities | 14M | 31M | 50M | 53M | 82M | 96M | 124M | 102M |
| Intangibles | N/A | 27M | 27M | 17M | 17M | 17M | 17M | 17M |
| Retained Earnings | -135M | -132M | -194M | -283M | -377M | -478M | -515M | -515M |
| Working Capital | 30M | 120M | 71M | 74M | 106M | 99M | 79M | 79M |
| Current Assets | 35M | 129M | 83M | 88M | 129M | 122M | 112M | 112M |
| Current Liabilities | 5.4M | 9.4M | 12M | 14M | 22M | 23M | 33M | 33M |
| Per Share Data | ||||||||
| EPS | -541.80 | -138.90 | -92.70 | -119.70 | -45.60 | -17.10 | -5.70 | -8.87 |
| Owner EPS | -587.86 | -130.60 | -96.38 | -19.05 | -39.17 | -17.85 | -21.29 | -1.28 |
| Book Value | 272.03 | 336.12 | 108.62 | 15.81 | 35.02 | 8.64 | 3.37 | 0.70 |
| Cash Flow/Share | -515.13 | -125.00 | -87.76 | -17.41 | -36.47 | -16.31 | -19.92 | -1.08 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.1M | 0.4M | 0.7M | 4.1M | 2.1M | 5.9M | 6.6M | 87.4M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 1.6 | 1.0 | 1.9 | 4.1 | 0.7 | 3.0 | 7.2 | 5.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 10.6 |
| FCF Yield | -120.3% | -38.5% | -43.9% | -27.1% | -143.5% | -63.0% | -82.8% | N/A |
| Market Cap | 34M | 125M | 137M | 264M | 54M | 153M | 158M | 361M |
| Avg. Price | 1,754.40 | 453.04 | 249.23 | 201.94 | 44.74 | 37.07 | 24.27 | 4.13 |
| Year-End Price | 428.40 | 325.80 | 204.30 | 64.80 | 25.44 | 25.92 | 24.12 | 4.13 |
X4 Pharmaceuticals, Inc passes 0 of 9 quality checks, indicating weak fundamentals.
X4 Pharmaceuticals, Inc (XFOR) has a 5-year average return on invested capital (ROIC) of -70.8%. This is below average and may indicate limited pricing power.
X4 Pharmaceuticals, Inc (XFOR) has a market capitalization of $361M. It is classified as a small-cap stock.
X4 Pharmaceuticals, Inc (XFOR) does not currently pay a regular dividend.
X4 Pharmaceuticals, Inc (XFOR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
X4 Pharmaceuticals, Inc (XFOR) generated $-131 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
X4 Pharmaceuticals, Inc (XFOR) has a debt-to-equity ratio of 3.41. This indicates higher leverage, which may increase financial risk.
X4 Pharmaceuticals, Inc (XFOR) reported earnings per share (EPS) of $-5.70 in its most recent fiscal year.
X4 Pharmaceuticals, Inc (XFOR) has a return on equity (ROE) of -102.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for X4 Pharmaceuticals, Inc (XFOR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
X4 Pharmaceuticals, Inc (XFOR) has a book value per share of $3.37, based on its most recent annual SEC filing.